The Ability of Rare Sugar Members to Release Glucagon-Like Peptide-1 and Suppress Food Intake in Mice

Rare sugars meet gut hormones

If you formulate with D-allulose, you now have a new reason to watch gut hormones. A 2025 paper in Nutrients (DOI: 10.3390/nu17071221) shows that this rare sugar can release active GLP-1 in mice and suppress food intake through a GLP-1-dependent pathway. That is a different story from the usual “sweetness with fewer calories” pitch.

Background: a functional sugar with a hormonal angle

Rare sugars occur naturally in small amounts. They deliver sweetness and low calories. That alone makes them attractive. But this study points to a deeper role.

The researchers focused on active GLP-1, a hormone tied to glucose control and food intake. They measured it in portal plasma. That blood compartment reflects gut-derived hormone release. For formulators, GLP-1 matters because it links sugar metabolism to appetite and glycemic control.

What the study did

The researchers gave mice a single oral gavage of D-allulose. Two doses were used: 1 g/kg and 3 g/kg. Then they measured active GLP-1 in portal plasma. They also tracked short-term food intake.

To test whether GLP-1 signaling caused the eating response, they pretreated some mice with exendin(9-39), a GLP-1 receptor antagonist.

This design has a clear logic. Raise GLP-1. See if food intake drops. Block the receptor. See if the effect disappears.

Key findings

The results were consistent.

Test	Result
Active GLP-1 after 1 g/kg D-allulose	Significantly increased in portal plasma
Active GLP-1 after 3 g/kg D-allulose	Significantly increased in portal plasma
Short-term food intake	Suppressed in a dose-dependent manner
Food intake after exendin(9-39)	Suppression was blocked

The dose-dependent response deserves attention. Food intake suppression grew with dose. The antagonist blocked it. That gives a mechanistic link. D-allulose did not simply fill the stomach. It activated a GLP-1 receptor-dependent pathway.

What this means for formulators

The authors describe rare sugars as promising functional food ingredients. They see potential in preventing overeating and supporting glycemic control. That is language ingredient buyers want to hear.

But read the study design carefully. This is a mouse model, not a human trial. The doses were single acute gavages. Human translation will depend on bioavailability, tolerance, and regulatory status. Still, the mechanistic proof matters. A rare sugar triggered active GLP-1 release in vivo.

For product developers, the implications are practical. If D-allulose already has a place in your reduced-sugar systems, this study adds another potential benefit. If the GLP-1 effect holds up in humans, the positioning changes. You would be selling more than sweetness. That changes how you position the product, who you target, and how you choose doses.

Watch for human studies using physiological doses. Also watch for comparisons with other rare sugars. This paper tested D-allulose. It does not prove every rare sugar behaves the same way.

FAQ

Is this a human study?

No. It is an acute study in mice. The results suggest potential, but human trials are required.

Why did the researchers measure portal plasma GLP-1?

Portal plasma is the blood closest to the gut and liver. Measuring active GLP-1 there gives a clearer picture of gut hormone release after ingestion.

What does exendin(9-39) do?

It is a GLP-1 receptor antagonist. When it was given, the food intake suppression from D-allulose was blocked. That shows GLP-1 receptor signaling is required for the effect.

Closing thoughts

D-allulose already has a strong story as a low-calorie sweetener. This paper adds a second act. It releases GLP-1, it suppresses food intake in mice, and the effect depends on GLP-1 signaling. That is the kind of evidence formulators can use to plan better products. The next round of research will tell us if the mouse translates to the human table.